The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2024 | Introducing the Universal Care Plan for patients with sickle cell disease in London
Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Trust, London, UK, provides insight into the new Universal Care Plan project, which has been launched for patients with sickle cell disease (SCD) living in London. The Universal Care Plan is an individualized document put together by a patient and their specialist care team and stored on a digital access platform where it can be viewed by any healthcare professionals (HCPs) involved in caring for the patient, including those who may be providing pain relief during acute pain episodes. Dr Chakravorty hopes this project will be expanded to other areas of the United Kingdom to improve patient care. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for participation in this meeting provided by Vertex Pharmaceuticals; Research funding: Pfizer, Global Blood Therapeutics, Forma therapeutics, Nova laboratories; Honoraria for EHA 2024 Congress: Vertex Pharmaceuticals, Sobi.
